HSPB1 and prostate carcinoma: OGX-427-mediated HSP27 suppression was reported to inhibit tumor proliferation and sensitize cancer cells to hormone, chemo-, and radiotherapies in hepatocellular carcinoma [13], prostate cancer [23], pancreatic cancer [24], non-small lung cancer [25], and head and neck cancer [26].